



COVID-19 and Mpox Situational Report in the ASEAN Region

— ASEAN BioDiaspora Virtual Center (ABVC)

December 19, 2022 | Issue No. 428



ASSOCIATION OF SOUTHEAST ASIAN NATIONS



ASEAN BIODIASPORA VIRTUAL CENTER (ABVC)



GLOBAL PARTNERS





Table of Contents

COVID-19	1
Highlights and Situation Overview	1
Global Update	1
Regional Update	1
Research Update	1
Travel Update	3
COVID-19 Cases and Deaths Table	4
COVID-19 Cases in ASEAN Region Table	4
COVID-19 Cases in Asia-Pacific Region Table	4
Epi curve Among ASEAN Countries	6
ASEAN Weekly New Cases and New Deaths	7
Vaccination Status in ASEAN	8
ASEAN Outlook Assessment	9
Mpox	10
Map of Mpox Cases Globally	10
Highlights and Situation Overview	11
Mpox Cases in ASEAN Region Table	11
Mpox Cases in Asia-Pacific Region Table	11
Top 5 Countries with Most Mpox Cases Globally	11
Mpox Cases per Region	12
Vaccine Update	12
References	13



COVID-19: Highlights and Situation Overview

Global Update

- **Worldwide**, there have been over 649 million cases and over 6 million deaths attributed to COVID-19.
- **China's** National Health Commission (NHC) officially reported on December 19 (Monday) its first two COVID-related deaths since December 3. The NHC also reported 1,995 symptomatic infections on December 18, compared with 2,097 a day earlier. The country stopped reporting asymptomatic cases last week citing a drop in mandatory PCR testing after China's shift in COVID-19 policies. Meanwhile, Macau's government announced on December 19 (Monday) that it would cancel its regulations on COVID-19 risk zones in mainland China starting from December 20 (Tuesday). Meanwhile, Shanghai has ordered most of its schools to take classes online as COVID-19 cases increase starting today (December 19). Nurseries and childcare centers will also close starting today.

Regional Update

- **Cambodia:** In Cambodia, four of the five age groups targeted for COVID-19 vaccine administration have exceeded 100% of the target numbers.⁴ As of December 17, the number of teenagers aged 18 and up vaccinated for the first dosage stood at 10,379,768 versus the planned 10 million. This accounted for 103.80% of the initial goal.⁴ Unfortunately, the number of persons who have been fully vaccinated with both the first and second doses is more than 330,000 lower than the number of people who have received their second dosage, which stands at 10,042,423.⁴ The percentage of people in the 12 to 18 age range targeted for vaccination amounted at 1,827,348 and the percentage which turned up for the immunization stands at 1,849,095 adolescents or 101.19% of the initial target.⁴ [\[Full Article\]](#)
- **Philippines:** The Department of Health is hoping that COVID-19 and Mpox will no longer be public health emergencies in 2023, as the global death toll from COVID-19 falls.⁵ Speaking to ABS-Sakto, CBN's DOH officer-in-charge Maria Rosario Vergeire said her office is very hopeful that public health emergency of the 2 illnesses will be lifted shortly following a World Health Organization proclamation.⁵ COVID-19 infections are increasing in the Philippines, according to Vergeire, since more Filipinos with COVID symptoms choose to employ antigen tests or self-isolate rather than contact a doctor.⁵ However, she stated the COVID statistics cannot be deemed critical since hospitals are still able to manage these instances.⁵ The DOH OIC said the health department continues to do genomic biosurveillance in the country but is no longer giving it focus "because no matter what subvariant comes in, the system can cope with it because of the vaccines and the hospitals can cope."⁵ She urged those who test positive for COVID-19 must always wear a mask and quarantine.⁵ [\[Full Article\]](#)

Research Update (Published and peer-reviewed studies)

- The study **SARS-CoV-2 infection and persistence in the human body and brain at autopsy** showed that SAR-CoV-2 virus spread throughout the body (including the brain) and lingered for almost 8 months.¹ Researchers analyzed tissue samples from the autopsies of 44 people who died of COVID-19 from April 2020 to March 2021.¹ All of the patients died of COVID-19, and none were vaccinated.¹ The blood plasma of 38 patients tested positive for SARS-CoV-2, 3 tested negative, and plasma was unavailable for the other 3.¹ Analysis of the study showed that SARS-CoV-2 primarily infected and damaged airway and lung tissue.¹ But the researchers also found viral RNA in 84 distinct



body locations and bodily fluids, and in one case they isolated viral RNA 230 days after a patient's symptoms began.¹ The researchers also detected SARS-CoV-2 RNA and protein in the hypothalamus and cerebellum of one patient and in the spinal cord and basal ganglia of two other patients.¹ According to the researchers, they found little damage to brain tissue "despite substantial viral burden."¹ [\[Full Text\]](#)

- This study, **Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial**, determined the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). Using a bayesian piecewise exponential model, it was observed that treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. [\[Full Text\]](#)
- On September 1, 2022, a single bivalent booster dose was recommended for adults who had completed a primary vaccination series (with or without subsequent booster doses), with the last dose administered ≥ 2 months earlier (1).² During September 13–November 18, this study, **Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022**, evaluated vaccine effectiveness (VE) of a bivalent mRNA booster dose (after 2, 3, or 4 monovalent doses) compared with 1) no previous vaccination and 2) previous receipt of 2, 3, or 4 monovalent-only mRNA vaccine doses, among immunocompetent adults aged ≥ 18 years with an emergency department/urgent care (ED/UC) encounter or hospitalization for a COVID-19–like illness.² VE of a bivalent booster dose (after 2, 3, or 4 monovalent doses) against COVID-19–associated ED/UC encounters was 56% compared with no vaccination, 31% compared with monovalent vaccination only with last dose 2–4 months earlier, and 50% compared with monovalent vaccination only with last dose ≥ 11 months earlier.² VE of a bivalent booster dose (after 2, 3, or 4 monovalent doses) against COVID-19–associated hospitalizations was 57% compared with no vaccination, 38% compared with monovalent vaccination only with last dose 5–7 months earlier, and 45% compared with monovalent vaccination only with last dose ≥ 11 months earlier.² Bivalent vaccines administered after 2, 3, or 4 monovalent doses were effective in preventing medically attended COVID-19 compared with no vaccination and provided additional protection compared with past monovalent vaccination only, with relative protection increasing with time since receipt of the last monovalent dose.² [\[Full Text\]](#)
- In this multicenter cohort study of more than 11 000 US mothers, **COVID-19 Pandemic Experiences and Symptoms of Pandemic-Associated Traumatic Stress Among Mothers in the US**, associations between pandemic-associated hardships, coping strategies, and behavior changes with pandemic-associated traumatic stress (PTS) symptoms were evaluated.³ OBJECTIVES To identify and describe clusters of mothers of children participating in the Environmental influences on Child Health Outcomes (ECHO) Program that characterize pandemic associated hardships, coping mechanisms, and behaviors, and to evaluate associations between pandemic-associated hardships, coping strategies, and behavior changes with pandemic-associated traumatic stress symptoms (PTS).³ The study surveyed 11 473 mothers (mean [SD] age, 37.8 [7.4] years; 342 American Indian [2.98%], 378 Asian [3.29%], 1701 Black [14.83%], and 7195 White [62.71%]; 2184 with Hispanic/ Latina ethnicity [19.04%]) and identified 2 clusters that best characterized their COVID-19 pandemic experiences—one characterized by higher life



disruptions (eg, to work and health care), higher social isolation, more coping behaviors to mitigate the outcomes of the pandemic, and more changes to their health behavior routines (high change [1031 mothers]) and the other characterized by lower changes (low change [3061 mothers]).³ The high change cluster was more socioeconomically advantaged and reported higher PTS (mean [SD] number of symptoms, 3.72 [2.44] vs 2.51 [2.47]).³ Across both clusters, higher pandemic-associated hardships, coping mechanisms, and behavior changes were associated with higher PTS, and these associations were greater in the low change cluster.³ [\[Full Text\]](#)

Travel Update

- **Macao SAR:** The government of Macao announced on December 19 (Monday) that all arrivals into Macau via the mainland, including from overseas, need to show a negative COVID test conducted within the last 72 hours from 48 hours previously.



COVID-19 Cases and Deaths as of 19 December 2022

- As of 19 December 2022 (2PM, GMT+8), worldwide, there were **649,048,837** confirmed cases, including **6,673,670** deaths. Globally, Case Fatality Rate (CFR) was **1.2%**.
- 35,458,055 confirmed cases** of COVID-19 have been reported in the **ASEAN Region**.
- The Case Fatality Rate in the **ASEAN Region** is range between **0.1 to 3.1%**.

COVID-19 cases in ASEAN region

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASEAN REGION	Brunei Darussalam	10 Mar 20	18-Dec-22	261,440	-	225	-	60,339	450,404	445,929	338,987	99.3
	Cambodia	27 Jan 20	18-Dec-22	138,387	25	3,056	-	839	15,226,312	14,590,810	10,358,897	87.0
	Indonesia	02 Mar 20	18-Dec-22	6,709,597	860	160,398	14	2,479	203,715,848	174,119,714	66,624,569	63.2
	Lao PDR	24 Mar 20	18-Dec-22	217,430	18	758	-	3,033	5,888,649	5,222,417		69.4
	Malaysia	25 Jan 20	18-Dec-22	5,017,863	847	36,806	6	15,705	28,117,401	27,528,452	16,877,358	81.1
	Myanmar	23 Mar 20	18-Dec-22	633,555	4	19,488	-	1,172	34,777,314	27,545,329	2,227,351	50.8
	Philippines	30 Jan 20	18-Dec-22	4,056,239	843	65,064	30	3,752	78,196,194	73,738,568	20,946,059	63.8
	Singapore	23 Jan 20	18-Dec-22	2,185,128	1,052	1,709	-	38,312	5,156,279	5,113,405	4,440,289	90.7
	Thailand	13 Jan 20	18-Dec-22	4,715,489	-	33,392	-	6,773	57,005,497	53,486,086	32,143,431	74.6
	Vietnam	23 Jan 20	18-Dec-22	11,522,927	177	43,179	-	11,946	90,156,999	84,690,714	56,988,856	86.3
ASEAN COUNTRIES				35,458,055	3,826	364,075	50	144,350	518,690,897	466,481,424	210,945,797	

*There have been no tests reported in the last 14 days in the ASEAN Region.

COVID-19 cases in Asia-Pacific region

REGION	COUNTRY/ TERRITORY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASIA-PACIFIC REGION	Afghanistan	24-Feb-20	18-Dec-22	207,037	94	7,845	1	544	11,320,910	10,615,628		25.8
	Australia	25-Jan-20	13-Dec-22	10,861,411	-	16,438	-	42,345	22,235,551	21,656,364	19,613,644	82.7
	Bangladesh	08-Mar-20	18-Dec-22	2,036,928	17	29,438	-	1,249	149,138,275	125,670,627	60,611,619	73.4
	Bhutan	05-Mar-20	14-Dec-22	62,521	-	21	-	8,193	699,116	677,669	634,641	86.6
	People's Republic of China*		18-Dec-22	11,312,858	33,306	31,307	0	68,195	1,334,003,248	1,300,815,376	209,906,904	89.1
	Cook Islands	17-Feb-22	14-Sep-22	6,389	-	1	-	29,872	15,084	14,715	10,209	86.4
	Fiji	18-Mar-20	04-Dec-22	68,451	-	878	-	7,692	711,429	640,282	169,174	68.9
	French Polynesia	12-Mar-20	13-Dec-22	77,646	-	649	-	27,802	190,765	186,059	112,237	60.8
	Guam	15-Mar-20	16-Dec-22	59,677	-	411	-	35,672	158,105	143,551		85.2
	India	30-Jan-20	18-Dec-22	44,675,952	176	530,672	5	3,270	1,027,087,217	950,909,151	221,686,727	67.1



	Japan	16-Jan-20	19-Oct-22	21,858,528	-	46,014	-	17,312	104,463,749	103,036,970	150,730,081	83.1
	Kiribati	25-Jan-22	25-Jul-22	3,430	-	13	-	2,917	96,184	73,888	23,419	56.3
	Maldives	07-Mar-20	13-Dec-22	185,651	-	311	-	34,966	399,146	385,076	167,176	73.5
	Marshall Islands	26-Oct-20	09-Dec-22	15,547	-	17	-	26,445	42,920	34,305		44.1
	Micronesia	11-Jan-21	31-Oct-22	22,203	-	55	-	19,508	83,562	70,339		68.7
	Mongolia	10-Mar-20	17-Dec-22	1,007,025	-	2,179	-	31,224	2,272,965	2,175,617	1,044,337	64.0
	Nepal	24-Jan-20	15-Dec-22	1,000,945	-	12,019	-	3,499	27,398,529	23,857,858	8,674,375	78.1
	New Caledonia	17-Mar-20	13-Dec-22	78,244	-	314	-	27,187	191,660	184,116	93,983	63.5
	New Zealand	28-Feb-20	12-Dec-22	2,019,685	-	3,371	-	41,076	4,299,152	4,137,155	3,479,861	79.8
	Niue	03-Sep-21	16-Dec-22	226	-	-	-	10,434	1,255	1,227	1,153	62.9
	Northern Mariana Islands	28-Mar-20	16-Dec-22	13,245	-	41	-	23,149	46,340	43,770		84.4
	Pakistan	26-Feb-20	18-Dec-22	1,575,585	13	30,635	-	728	139,644,465	132,317,738	48,935,695	56.1
	Palau	31-May-21	13-Dec-22	5,933	-	9	-	32,946	20,714	18,458		85.7
	Papua New Guinea	21-Mar-20	13-Dec-22	46,457	-	669	-	529	364,894	304,687	30,676	3.0
	Samoa	18-Nov-20	25-Nov-22	15,967	-	29	-	8,101	231,546	215,077	79,061	96.7
	Solomon Islands	03-Oct-20	24-Nov-22	24,575	-	153	-	3,669	343,821	254,352	27,783	35.1
	Republic of Korea**	20-Jan-20	18-Dec-22	28,188,293	16,220	31,395	16	54,513	45,134,185	44,704,644	41,324,379	86.3
	Sri Lanka	27-Jan-20	18-Dec-22	671,813	5	16,814	-	3,081	17,143,761	14,752,827	8,220,002	67.6
	Timor Leste	21-Mar-20	16-Dec-22	23,379	-	138	-	1,808	872,617	779,475	291,233	58.1
	Tonga	05-Nov-21	06-Sep-22	16,182	-	12	-	15,486	91,949	77,464	38,331	72.5
	Türkiye	10-Mar-20	12-Dec-22	17,041,315	-	101,487	-	20,426	57,941,051	53,176,961	41,425,329	62.3
	Vanuatu	11-Nov-20	02-Nov-22	11,952	-	14	-	3,986	144,824	131,697	16,996	40.3
	Wallis et Futuna	17-Oct-20	28-Jul-22	761	-	7	-	4,749	7,136	6,794	3,742	58.6
	ASIA PACIFIC			143,195,811	49,831	863,356	22	612,570	2,946,796,125	2,792,069,917	817,352,767	

*Includes cases from Hong Kong (SAR), Macau (SAR), and Taiwan (Province of China).

**Republic of Korea – South Korea


- **469,540,945 confirmed cases** of COVID-19 have been reported in other **4 regions** (other than ASEAN and Asia-Pacific countries):

REGION	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED
AFRICA	12,994,390	263	259,250	4	247,397	456,803,234	371,428,151	59,674,628
AMERICAS	187,635,989	12,111	2,917,448	32	1,222,490	833,064,252	732,578,368	485,674,326
EUROPE	247,132,238	45,897	2,030,765	61	2,080,181	568,607,674	539,597,834	376,059,987
MIDDLE EAST	22,632,354	982	238,776	5	214,908	144,506,725	129,815,862	59,968,391
TOTAL	470,394,971	59,253	5,446,239	102	3,764,976	2,002,981,885	1,773,420,215	981,377,332



COVID-19 Epi curve among ASEAN Countries:


From January 1, 2021 to December 18, 2022





ASEAN Weekly COVID-19 New Cases and New Deaths


From January 1, 2021 to December 18, 2022





ASEAN COVID-19 Vaccination Status



as of 18 December 2022





ASEAN COVID-19 Outlook Assessment

as of 16 December 2022


  ASEAN MEMBER STATE	<p>At least 65% of the total population has a level of immunity to COVID-19; either recovered from COVID-19 or have been vaccinated with at least one dose of a COVID-19 vaccine.</p>				<p>Case levels are generally low (a 7-day rolling average number of daily new cases that is <10 cases per 100,000, with each day's past-14-day test positivity is consistently <5%).</p>	<p>Government Policy on containment and health (strictness and comprehensiveness in COVID-19 related government policies)</p>
	% of Total population fully vaccinated / boosted	Population vaccinated/ day (7-day average)	Daily cases/ 100,000	Containment and health index score - Oxford COVID-19 Government Response Tracker (OxCGRT)		
Brunei Darussalam	≥90.0/75.5	Unknown	672.47	31.0/100		
Cambodia	≥90.0/61.8	Unknown	0.13	31.5/100		
Indonesia	66.7/24.2	Unknown	0.72	54.2/100		
Lao PDR	77.3/ND	Unknown	0.61	61.6/100		
Malaysia	84.5/49.7	0%/day	3.60	51.8/100		
Myanmar	52.1/4.1	Unknown	0.04	69.1/100		
Philippines	71.4/18.1	Unknown	1.01	55.4/100		
Singapore	≥90.0/78.8	Unknown	21.58	58.9/100		
Thailand	77.7/44.8	Unknown	0.81	31.5/100		
Vietnam	≥90.0/58.0	Unknown	0.38	43.5/100		

All of the countries have achieved the Population vaccinated/ day (7-day average) except Vietnam.



Mpox (Monkeypox) Cases Reported Globally

as of December 18, 2022





Mpox: Highlights and Situation Overview

- As of 19 December 2022 (2PM, GMT+8), worldwide, there were **87,819** confirmed cases, including **213** deaths. Globally, Case Fatality Rate (CFR) was **0.24%**.
- 40 confirmed cases** in the ASEAN region, with CFR of **0%**.
- 87,779 confirmed cases** of Mpox have been reported in other **5 regions** (other than ASEAN region):

Mpox cases in ASEAN region

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Indonesia	1	-	-	0.00%
Philippines	4	-	-	0.00%
Singapore	19	-	-	0.00%
Thailand	12	-	-	0.00%
Vietnam	4	-	-	0.00%
ASEAN Total	40	-	-	0.00%

Mpox cases in Asia-Pacific region

Country/Territory	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Australia	144	-	-	0.00%
Hong Kong (SAR)	1	-	-	0.00%
India	23	-	1	5.00%
Japan	7	-	-	0.00%
New Caledonia	1	-	-	0.00%
New Zealand	40	-	-	0.00%
People's Republic of China*	9	-	-	0.00%
Republic of Korea*	4	-	-	0.00%
Sri Lanka	2	-	-	0.00%
Asia-Pacific Total	231	-	1	0.45%

*People's Republic of China – including Hong Kong (SAR), Macao (SAR), and Taiwan (Province of China)

Top 5 countries with most mpox cases globally

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
United States of America	29,646	-	20	0.07%
Brazil	10,264	12	14	0.14%
Spain	7,416	4	3	0.04%
France	4,110	-	-	0.00%
Colombia	3,908	-	-	0.00%

*Adjusted cases from previous report



Mpox cases per region

REGION	TOTAL CONFIRMED CASES SINCE JANUARY 1, 2022	NEW CASES SINCE THE PREVIOUS REPORT	TOTAL DEATHS	CASE FATALITY RATE
AFRICA	5,137	-	160	3.11%
AMERICAS	56,091	31	47	0.08%
ASEAN	40	-	-	0.00%
ASIA PACIFIC	231	-	1	0.43%
EUROPE	26,001	-	4	0.02%
MIDDLE EAST	319	-	-	0.00%
TOTAL	87,819	31	213	0.24%

Vaccine Update

- Trinidad and Tobago:** The term "responsibility" refers to the act of determining whether or not a person is responsible for his or her own actions.⁶ In a statement the Ministry stated this is the first of two shipments under the Pan American Health Organization (PAHO) vaccine purchasing network.⁶ According to the Ministry, the second consignment of 1,400 dosages is expected to arrive in the country soon.⁶ This would equate to a total of 2,800 doses of the locally available two-dose "mpox" vaccinations.⁶ The WHO interim guidelines will be adopted by the Ministry of Health on November 16th, 2022.⁶



References

1. Stein, Sydney R., et al. "SARS-COV-2 Infection and Persistence in the Human Body and Brain at Autopsy." *Nature*, 14 Dec. 2022, <https://doi.org/10.1038/s41586-022-05542-y>.
2. Tenforde, Mark W., et al. "Early Estimates of Bivalent Mrna Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations among Immunocompetent Adults — Vision Network, Nine States, September–November 2022." *MMWR. Morbidity and Mortality Weekly Report*, vol. 71, no. 5152, 16 Dec. 2022, <https://doi.org/10.15585/mmwr.mm715152e1>.
3. Bastain, Theresa M., et al. "Covid-19 Pandemic Experiences and Symptoms of Pandemic-Associated Traumatic Stress among Mothers in the US." *JAMA Network Open*, vol. 5, no. 12, 16 Dec. 2022, <https://doi.org/10.1001/jamanetworkopen.2022.47330>.
4. "Close to 1.2 Million People in Cambodia Have Received Their 5th Dose of COVID-19 Vaccine - Khmer Times." *Khmer Times - Insight into Cambodia*, 18 Dec. 2022, <https://www.khmertimeskh.com/501204398/close-to-1-2-million-people-in-cambodia-have-received-their-5th-dose-of-covid-19-vaccine/>.
5. "Doh Hopeful for End to COVID, Mpox Emergencies in 2023." *ABS-CBN News*, ABS-CBN News, 19 Dec. 2022, <https://news.abs-cbn.com/news/12/19/22/doh-hopeful-for-end-to-covid-mpox-emergencies-in-2023>.
6. Doodnath, Alina. "Health Ministry Receives 1,400 Monkeypox Vaccines: Loop Trinidad & Tobago." *Loop News*, Loop News, 14 Dec. 2022, <https://tt.loopnews.com/content/health-ministry-receives-1400-monkeypox-vaccines>.



Report generated by
ASEAN Biodiaspora Virtual Center (ABVC)
in collaboration with **Bluedot Inc.**
Email: support@biodiaspora.org
Facebook: <https://facebook.com/ASEANBiodiaspora>



In partnership with
Canada